Key result
Suloctidil cuts new thrombotic events by ~100% vs placebo in idiopathic recurrent vein thrombosis.
Why the study?
Idiopathic recurrent vein thrombosis patients previously unsuccessfully treated with VKA or ASA require evaluation of alternative antiplatelet therapies such as suloctidil.
Does suloctidil prevent new thrombotic events in patients with idiopathic recurrent vein thrombosis?
RCT (n=31)
Double-blind
Does suloctidil prevent new thrombotic events in patients with idiopathic recurrent vein thrombosis?
Suloctidil completely prevented new thrombotic events over 6 months in patients with idiopathic recurrent vein thrombosis who had previously failed standard therapy, compared to a high event rate on placebo.
Answers are grounded in this paper and cite their sources.
Suloctidil offers effective secondary prevention after standard therapy failure in idiopathic recurrent vein thrombosis; confirms benefit in this crossover RCT.
A double blind cross over study with suloctidil (Sulocton, Continental Pharma) and placebo was carried out for 6 months in 31 patients with idiopathic recurrent vein thrombosis. They were previously unsuccessfully treated with vitamin K antagonists (VKA) (18 patients) or acetylsalicylic acid (ASA) (13 patients) combined or not the a fibrinolysis activator (theophylline nicotinate). Clinical features, ultrasonic venous flow and biological parameters were controlled monthly during the 6 month treatment. Relevant improvement of clinical, ultrasonic and biological parameters was only observed under suloctidil therapy: during placebo administration 12 patients developed new thrombotic events complicated in 2 by pulmonary embolism while none occurred under suloctidil therapy.
No takes yet. Share an insight, caveat, or question.
Moriau et al. (1982) conducted an RCT in Idiopathic recurrent vein thrombosis (n=31). Suloctidil vs. Placebo was evaluated on New thrombotic events. Suloctidil prevented new thrombotic events compared to placebo in patients with idiopathic recurrent vein thrombosis over a 6-month cross-over period.
Synapse has enriched 10 related papers. Consider them for comparative context: